Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio

Executive Summary

The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.

You may also be interested in...



Three EU Countries Strike Landmark Joint Zolgensma Pricing Deal

BeNeLuxA, the cross-country medicines access initiative, says it is now the “gold standard” for voluntary collaboration in Europe after a ground-breaking deal was reached with Novartis.

Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel

ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.

Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing

The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel